<DOC>
	<DOCNO>NCT00861809</DOCNO>
	<brief_summary>The purpose study assess pharmacodynamic effect ( gastric emptying ) , safety , tolerability , pharmacokinetics single dos GSK962040 Type 1 diabetic patient gastroparesis .</brief_summary>
	<brief_title>The Effect Single Doses Motilin Receptor Agonist GSK962040 Type I Diabetic Patients With Gastroparesis</brief_title>
	<detailed_description />
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Motilin</mesh_term>
	<criteria>Controlled Type 1 Diabetes Mellitus ( glucose &lt; 250 mg/dL ) onset &lt; 30 year age . Male female 18 70 year age , inclusive . Patient document diagnosis moderate severe gastroparesis ( &gt; 30 % 2 h determine scintigraphy ; t1/2b &gt; 109 min determine 13Coctanoic acid breath test ) . All following apply : Confirmed delay gastric emptying ( properly conduct gastric empty assessment within last 6 month acceptable ) AND minimum 3 month history relevant symptom gastroparesis ( e.g. , chronic postprandial fullness , postprandial nausea , vomit ) A female patient eligible participate : Nonchildbearing potential Childbearing potential agrees use contraception least 4 day follow last dose study medication . Male patient must agree use contraception time first dose study medication least 4 day last dose study medication . Body weight ≤110 kg BMI &lt; 32.0 kg/m2 ( inclusive ) . Patient never gastrectomy , major gastric surgical procedure evidence bowel obstruction within previous 12 month Dosage concomitant medication stable least 3 week , except routine adjustment daily insulin treatment HbA1c level ≤ 10.0 % Calculated creatinine clearance &gt; equal 50 ml/min QTcB QTcF &lt; 450 msec QTc &lt; 480msec patient Bundle Branch Block base single average QTc value triplicate value obtain brief recording period . AST , ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Capable give write informed consent , include compliance requirement restriction list consent form . Patient acute severe gastroenteritis Patient gastric pacemaker Patient chronic parenteral feeding Patient daily persistent severe vomit Patient pronounce dehydration Patient clinical diabetic ketoacidosis last 4 week Patient history eat disorder ( anorexia nervosa , binge eating , bulimia ) Use medication potentially influence upper gastrointestinal motility appetite within one week study ( e.g. , prokinetic drug , macrolide antibiotic ( erythromycin ) ) Patient take opiate . Use prohibit medication list Section 9.2 within restrict timeframe relative first dose study medication . History presence clinically significant gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . Presence thyroid dysfunction ( NOTE : patient abnormal TSH screening/baseline eligible . Patients history hypothyroidism stable dose thyroid replacement therapy eligible participate study ) . The patient participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test ( first urine day ) screen prior dosing . Lactating pregnant female . Unwillingness inability follow procedure outline protocol . Patients deem unable comply procedure outline protocol may exclude Investigator 's discretion . For male volunteer : An unwillingness male patient comply contraception requirement list Section 8.1 , time first dose study medication least 4 day follow administration last dose study medication . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>single dose</keyword>
	<keyword>gut motility</keyword>
	<keyword>Type I Diabetes Mellitus patient</keyword>
	<keyword>tolerability</keyword>
	<keyword>phase II</keyword>
	<keyword>13C octanoic acid breath test</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>gastric emtpying</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>